Exploring the Effect of BRCA1/2 Status on Chemotherapy-induced Hematologic Toxicity in Patients with Ovarian Cancer

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2024 Apr 23

PMID 38652271

Authors

In Hee Lee

Soo Jung Lee

Juhyung Kim

Yoon Hee Lee

Gun Oh Chong

Jong Mi Kim

Juhun Lee

Nan Young Lee

Seo Young Park

Dea Gy Hong

Yee Soo Chae

Affiliations

Soon will be listed here.

Abstract

Objective: BRCA1/2 are integral to the DNA repair mechanism and their germline pathogenic variants (gBRCA) result in a high risk for developing breast and ovarian cancer. Patients with gBRCA mutations showed increased sensitivity to DNA cross-linking agent but might have increased treatment-related toxicities. Thus, we hypothesized that gBRCA mutation ovarian cancer patients who underwent platinum-based chemotherapy might be at higher risk of developing chemotherapy-induced hematologic toxicity.

Methods: This study enrolled 160 patients with ovarian cancer who received frontline platinum-based chemotherapy between 2011 and 2019 in Kyungpook National University Chilgok Hospital. Incidence rate and severity of chemotherapy-induced hematologic toxicity (neutropenia, anemia, thrombocytopenia) was compared for BRCA mutation and wild patients.

Results: 160 women, including 62 BRCA1/2 (38 BRCA1, and 25 BRCA2) mutation group, and 98 noncarriers, were analyzed. A higher frequency of G2 anemia was noted in the BRCA -mutant group (22% vs. 1%, p = 0.07). Furthermore, G3 anemia was significantly common among BRCA group (12.9% vs. 3%, p = 0.02). In the subgroup analysis according to BRCA1/2 status, BRCA1 mutated patients showed a significantly higher frequency of G1 anemia than BRCA2 (89% vs. 60%, p = 0.01). In terms of neutropenia and thrombocytopenia, BRCA mutated patients and noncarriers had similar hematologic toxicity.

Conclusion: Germline BRCA mutations were associated with a higher frequency of G2/3 anemia in ovarian cancer patients who underwent first-line platinum-based chemotherapy. Moreover, the BRCA1 mutation appeared to be more strongly associated with the incidence of chemotherapy-induced anemia. Our findings warrant further investigation in larger, prospective studies to confirm these current findings and determine whether preventive interventions may be necessary.

References

Banerjee S, Kaye S . New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013; 19(5):961-8. DOI: 10.1158/1078-0432.CCR-12-2243. View

Daly M, Axilbund J, Buys S, Crawford B, Farrell C, Friedman S . Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010; 8(5):562-94. DOI: 10.6004/jnccn.2010.0043. View

Turner N, Tutt A, Ashworth A . Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004; 4(10):814-9. DOI: 10.1038/nrc1457. View

Nielsen F, Hansen T, Sorensen C . Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer. 2016; 16(9):599-612. DOI: 10.1038/nrc.2016.72. View

Helleday T, Petermann E, Lundin C, Hodgson B, Sharma R . DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008; 8(3):193-204. DOI: 10.1038/nrc2342. View

Negrini S, Gorgoulis V, Halazonetis T . Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010; 11(3):220-8. DOI: 10.1038/nrm2858. View

Gonzalez-Martin A, Pothuri B, Vergote I, Christensen R, Graybill W, Mirza M . Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019; 381(25):2391-2402. DOI: 10.1056/NEJMoa1910962. View

Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M . Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26):2495-2505. DOI: 10.1056/NEJMoa1810858. View

Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R . Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019; 381(25):2416-2428. DOI: 10.1056/NEJMoa1911361. View

10.

Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G . Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. ESMO Open. 2021; 6(5):100238. PMC: 8371213. DOI: 10.1016/j.esmoop.2021.100238. View

11.

Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T . Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 2012; 14(4):R110. PMC: 3680929. DOI: 10.1186/bcr3231. View

12.

Deshpande M, Paniza T, Jalloul N, Nanjangud G, Twarowski J, Koren A . Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells. Mol Cell. 2022; 82(20):3781-3793.e7. DOI: 10.1016/j.molcel.2022.08.017. View

13.

Mgbemena V, Signer R, Wijayatunge R, Laxson T, Morrison S, Ross T . Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function. Cell Rep. 2017; 18(4):947-960. PMC: 5267932. DOI: 10.1016/j.celrep.2016.12.075. View

14.

Sedic M, Skibinski A, Brown N, Gallardo M, Mulligan P, Martinez P . Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun. 2015; 6:7505. PMC: 4491827. DOI: 10.1038/ncomms8505. View

15.

Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C . BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun. 2014; 5:5496. PMC: 4243249. DOI: 10.1038/ncomms6496. View

16.

Konishi H, Mohseni M, Tamaki A, Garay J, Croessmann S, Karnan S . Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011; 108(43):17773-8. PMC: 3203756. DOI: 10.1073/pnas.1110969108. View

17.

Kottemann M, Smogorzewska A . Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature. 2013; 493(7432):356-63. PMC: 3700363. DOI: 10.1038/nature11863. View

18.

Hu-Heimgartner K, Lang N, Ayme A, Ming C, Combes J, Chappuis V . Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature. Fam Cancer. 2023; 22(3):283-289. PMC: 10276105. DOI: 10.1007/s10689-023-00331-6. View

19.

Kwon B, Byun J, Lee H, Jeong D, Lee T, Shin K . Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review. Cancer Res Treat. 2018; 51(3):941-950. PMC: 6639209. DOI: 10.4143/crt.2018.312. View

20.

Kang E, Kim S . The korean hereditary breast cancer study: review and future perspectives. J Breast Cancer. 2013; 16(3):245-53. PMC: 3800720. DOI: 10.4048/jbc.2013.16.3.245. View